Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AMRI, which works on drug discovery and development projects and conducts manufacturing of active ingredients and pharmaceutical intermediates for healthcare companies, has named David Lathbury as vice president of Chemical Development.
Subscribe to our email newsletter
Lathbury is expected to report to Steven Hagen, vice president of Pharmaceutical Development and Manufacturing.
Lathbury will assume leadership for AMRI’s Chemical Development business including operations in Albany, Rensselaer and Syracuse, New York and also be responsible for the coordination of global projects spanning all AMRI chemical development operations, including the company’s sites in Wales, UK and Hyderabad, India for purposes of further optimising operations and technology transfer activities.
Lathbury brings to AMRI over 23 years of industrial experience in process development and optimisation, scale up and technical transfer of products in the pharmaceutical and agrochemical industry.
Most recently, Lathbury served as director of Process Chemistry for AstraZeneca Process Research and Development (PR&D) where he was actively involved in setting PR&D strategy for AstraZeneca’s Discovery/PR&D interface and outsourcing functions.
Prior to AstraZeneca, he spent seven years at Smithkline Beecham Pharmaceutical’s Synthetic Chemistry division focusing on process development and technology transfer, culminating in the role of team leader.
AMRI chairman, president and CEO Thomas D’Ambra said that they were excited to recruit Lathbury at this critical time in the international expansion of their chemical development and manufacturing operations.